**PATENT** 

Application No.: 09/017,785

Page 2

Serial No. 08/159,184, filed 11/29/93, U.S. Serial No. 08/073,205 filed 6/4/93, U.S. Serial No. 08/027,146 filed 3/5/93. All of such above-referenced applications are incorporated herein by reference.--

TOWNSEND SF

Please insert the following heading and paragraph before the BACKGROUND OF THE INVENTION on page 1 at line 8:

## -FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was funded, in part, by the United States government under grants with the National Institutes of Health. The U.S. government has certain rights in this invention.--

## IN THE CLAIMS:

Please cancel claims 1-8.

Please and the following new replacement claims 9-62.

A method of inducing an immune response with a peptide √9. (new) comprising an epitope consisting of about 8-11 residues that will bind to an HLA-A2.1 molecule and induce an HLA-A2.1-restricted cytotoxic T cell response, said method comprising steps of:

providing a peptide comprising a putative T cell epitope, said putative epitope comprising a structural motif associated with peptide binding to HLA-A2.1, said structural motif comprising a first anchor amino acid at position two from an N-terminus of the epitope, said first anchor selected from the group consisting of V, A, and T, and a second anchor amino acid selected from the group consisting of L, I, V, M and A at a carboxyl-terminus of the epitope, said peptide connected to another molecule to create a compound with a proviso that neither said peptide, said another molecule nor said compound comprise an entire native antigen;

complexing the provided peptide, or a fragment thereof which comprises the epitope, with an HLA molecule; and,

contacting a cytotoxic T lymphocyte (CTL) with the complex, whereby a CTL response is induced.